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TaiwanMethods: Three thousand and eighty confirmed ACS patients enrolled in this registry were fol-
lowed up for 1 year at 3-month intervals. Patient data on medical interventions as well as clin-
ical events were recorded and analyzed by descriptive statistics.
Results: One-year mortality among patients with ST-segment elevation myocardial infarction
(STEMI), non-STEMI (NSTEMI) and unstable angina was 6.1%, 10.1%, and 6.2%, respectively.
Use of secondary preventive therapies was suboptimal throughout the follow-up phase, espe-
cially dual antiplatelet therapy, which fell from 74.8% patients at discharge to 24.9% patients
at 1-year follow-up. The odds of an adverse incidence of death/myocardial infarction/stroke
1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for
9 months and was consequently higher in patients in whom dual antiplatelet therapy was dis-
continued or prescribed for <9 months. Chronic renal failure, in-hospital bleeding, a diagnosis
of NSTEMI, and antiplatelet therapy discontinuation had a negative association with 1-year
outcomes, whereas the use of drug-eluting stents and antiplatelet agents, clopidogrel and
aspirin, were predictors of positive outcomes.
Conclusion: There is a significant deviation from evidence-based guidelines in ACS manage-
ment in Taiwan as reported in other countries. Policy adherence, especially with regard to dual
antiplatelet therapy may hold the key to long-term favorable outcomes and improved survival
rates in ACS patients in Taiwan.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Evidence-based guidelines for the management of acute
coronary syndrome (ACS) have been established by the
American College of Cardiology Foundation (ACCF)/
American Heart Association (AHA)1,2 and the European
Society of Cardiology3 with recent updates regarding
the use of particular antiplatelet and antithrombotic
therapies.4,5,6,7,8,9 However, observations from various
large studies such as Can Rapid Risk Stratification of
Unstable Angina Patients Suppress Adverse Outcomes
With Early Implementation of the ACC/AHA Guidelines
(CRUSADE),10 Global Registry of Acute Coronary Events
(GRACE),11,13 Acute Coronary Syndrome Prospective
Audit (ACACIA),14 Clinical Pathways for Acute Coronary
Syndromes in China (CPACS)15 and the Canadian
Acute Coronary Syndromes (CACS) registry16 have indi-
cated that the use of these guidelines is suboptimal.
The Taiwan Acute Coronary Syndrome Descriptive Reg-
istry (T-ACCORD),17 a registry of unstable angina (UA)
and non-ST-elevation myocardial infarction (NSTEMI)
cases, has shown that a similar lag exists in ACS man-
agement in Taiwan as well.
To meet the need for a nationwide Taiwanese registry
that covers the full spectrum of ACS and assesses current
clinical practices/outcomes, this study was undertaken.
The Taiwan ACS Full Spectrum Registry was a prospective
study carried out at various medical centers and regional
hospitals in Taiwan in patients presenting with ACS symp-
toms. The main goal of the registry was to identify whether
the current practices in ACS management throughout
Taiwan were in concordance with established guidelines.
The baseline characteristics and in-hospital outcomes
published previously substantiated the discord between
clinical guidelines and real-world practice especially with
regard to invasive management and secondary preventive
therapy.18 The objective of this study is to present the
predictors of outcomes in Taiwanese ACS patients up to
1 year after hospitalization.Methods
Study patients
Patients included in this study had been enrolled in the ACS
Full Spectrum Registry reported previously.18 Briefly, be-
tween October 2008 and January 2010, 3183 consecutively
eligible patients aged 20 years, presenting with symptoms
of ACS and admitted within 24 hours at any of the 39
participating study sites in Taiwan, were recruited for the
study. Following discharge, patients were followed up for a
period of 1 year at 3-month intervals and data were
collected on prescribed medical interventions as well as
clinical events such as myocardial infarction (MI), stroke,
rehospitalization, and death.
All patients had to provide a signed consent and the
study protocol was approved by the institutional ethics
committee at each site. The study was carried out in
accordance with local regulatory guidelines as well as in-
ternational guidelines for Good Epidemiological Practice.19Statistical analysis
Sample size was calculated taking the following into
consideration: the known incidence rate of 0.0025, a power
of 80% to detect an additional incidence of 0.003, and an
anticipated dropout rate of 20%.
Descriptive statistics was used to evaluate study
parametersdmean, median and standard deviation for
continuous data and counts and percentages for categorical
data. Cox proportional hazards modeling was used to
analyze the impact of clinical and demographic covariates
on survival and “event-free survival”. Propensity score
matching was used to adjust for nonrandomized compari-
sons when appropriate. All statistical analyses were carried
out with a two-sided a-level of <0.05. Patients who were
“lost to follow-up” were censored at the time of last con-
tact and assumed to be alive and “event-free”. All
796 F.-T. Chiang et al.statistical analyses were carried out using SAS version 9.2
(SAS Institute, Cary, NC, USA). A p value of less than 0.05 is
considered statistically significant.
Results
The baseline characteristics of patients from this registry
have been reported previously.18 The mean age of the
enrolled patients was 63.1  13.6 years and 78.0% of the
patients were males. More than half (52.3%) of the patients
had a final diagnosis of ST-segment elevation myocardial
infarction (STEMI). Percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG) was per-
formed in 84.4% and 3.3% of the patients, respectively. Dual
antiplatelet therapy with aspirin and clopidogrel was pre-
scribed to 74.8% patients at discharge. Other frequently
prescribed drugs at discharge were renin-angiotensin sys-
tem blockers (63.0%), statins (60.5%) and beta-blockers
(53.4%). Overall in-hospital mortality was 1.8% with the
highest mortality rate (2.3%) in STEMI cases.
One-year outcomes
Of the 3080 confirmed ACS patients discharged post hospi-
talization, 2498 were alive 1 year later (Fig. 1). A total of
202 deaths were reported: 51 during hospitalization and
151 at 1-year follow-up. A total of 431 patients were either
lost to follow-up or withdrawn from the study. Although
overall patient mortality was at 7.5% in patients with ACS,Figure 1 Patient disposition in the Taiwan ACS Full Spectrum R
segment elevation myocardial infarction; STEMI Z ST-segment elethis was more pronounced at 10.1% in the NSTEMI cases
(Table 1). MI and stroke was reported in 4.8% and 2.0%
patients, respectively. A total of 1131 (42.3%) patients had
to be rehospitalized within the year after index hospitali-
zation. Almost one-fifth of the patients (20.1%, n Z 512)
had to undergo either repeat revascularization, PCI or
CABG, but the rates had no association with the type of ACS
except in NSTEMI patients who underwent CABG procedure
more frequently than others (22 of 840, 2.6%). Death/MI/
stroke was observed in 345 (12.7%) patients, and this rate
was higher in NSTEMI cases (16.8%, p < 0.01). An adverse
outcome, defined as the incidence of death, rehospitali-
zation, stroke, MI or the requirement for revascularization
was reported in almost half of the patients (45.4%,
nZ 1267). Adverse outcomes were more pronounced in the
NSTEMI cases (48.0%; p Z 0.044).Medication at discharge and through follow-up
Table 2 lists the drugs prescribed to the patients all
throughout the study. At discharge, antiplatelet-
antithrombotic therapy using aspirin and clopidogrel,
either alone or in combination with each other, was re-
ported in >90% of the patients. Although aspirin alone was
prescribed to only 5.5% patients at release, it was reported
in 51.7% of the patients at 1-year follow-up. Moreover, the
combination of aspirin and clopidogrel prescribed to 74.8%
patients at discharge was reported in only 24.9% patients a
year later. The number of patients receiving clopidogrelegistry. ACS Z acute coronary syndromes; NSTEMI Z non-ST-
vation myocardial infarction; UA Z unstable angina.
Table 1 Clinical outcomes from enrolment to 1-year follow-up.
n (%) p
Total STEMI NSTEMI UA
Death 202 (7.5) 88 (6.1) 93 (10.1) 21 (6.2) <0.01
Rehospitalization 1131 (42.3) 592 (41.9) 410 (44.5) 129 (37.8) 0.093
Stroke 50 (2.0) 22 (1.6) 21 (2.5) 7 (2.2) 0.337
MI 121 (4.8) 64 (4.7) 54 (6.4) 3 (0.9) <0.01
Repeat revascularization 179 (7.1) 99 (7.3) 56 (6.6) 24 (7.5) 0.815
PCI 450 (17.7) 259 (18.9) 143 (16.8) 48 (14.8) 0.162
CABG 41 (1.6) 14 (1.0) 22 (2.6) 5 (1.6) 0.017
Revascularization (repeat/PCI/CABG) 512 (20.1) 284 (20.7) 171 (20.0) 57 (17.5) 0.427
Composite of death or MI or stroke 345 (12.7) 162 (11.2) 156 (16.8) 27 (8.0) <0.01
Composite of death, rehospitalization, stroke, MI and
revascularization
1267 (45.4) 661 (44.8) 464 (48.0) 142 (40.5) 0.044
CABG Z coronary artery bypass grafting; MI Z myocardial infarction; NSTEMI Z non-ST-segment elevation myocardial infarction;
PCI Z percutaneous coronary intervention; STEMI Z ST-segment elevation myocardial infarction; UA Z unstable angina.
One-year predictors of acute coronary syndrome 797alone did not change much. This implies a shift from the use
of dual therapy to the use of single-agent in ACS patients
post hospitalization (Fig. 2). The most commonly cited
reason for discontinuation of clopidogrel within 9 months of
the dual antiplatelet therapy was the Bureau of National
Health Insurance (BNHI) regulations in Taiwan (reported in
41.0% of the patients) followed by physician judgment
(Table 3).
At hospital discharge and thereafter, statins were most
commonly prescribed medication, in over 60% of the pa-
tients, followed by beta blockers in >50%. An angiotensin-
converting enzyme (ACE) inhibitor or an angiotensin re-
ceptor blocker (ARB) was also prescribed in >50% of the
patients. Additionally, there was a decreasing trend in the
use of ACE inhibitors at prospective follow-up visits while in
contrast, the usage of ARB increased at successive visits.Predictors of 1-year outcome of death, MI or stroke
The highest probability of death/MI/stroke within the year
after hospitalization was seen in patients with a medicalTable 2 Secondary preventive medicine usage throughout the
Medication
At discharge 3-mo FU
Aspirin or clopidogrel
Aspirin only 174 (5.5) 429 (14.4
Clopidogrel only 313 (9.8) 403 (13.6
Aspirin þ clopidogrel 2381 (74.8) 1980 (66.7
ACEI 1408 (44.2) 911 (30.7
ARB 621 (19.5) 957 (32.2
Beta blocker 1700 (53.4) 1726 (58.1
Calcium channel blocker 425 (13.4) 521 (17.5
Lipid-lowering agents
Statin 1924 (60.5) 1806 (60.8
Others 131 (4.1) 117 (3.9)
ACEI Z angiotensin-converting enzyme inhibitor; ARB Z angiotensinhistory of chronic kidney failure (odds ratio [OR] Z 4.54;
p < 0.01; Fig. 3) or an incidence of bleeding during the
hospitalization (ORZ 3.87; p < 0.01). Patients with NSTEMI
were also more likely (ORZ 1.38, p < 0.01) to have death/
MI/stroke within the 1-year period. Most medications pre-
scribed at discharge had a favorable response in lowering
the odds against death/MI/stroke, especially aspirin
(OR Z 0.35, p < 0.01) and clopidogrel (OR Z 0.34,
p < 0.01). This observation is corroborated by the huge
upsurge in the probability of death/MI/stroke in ACS pa-
tients in whom antiplatelet therapy was discontinued
(OR Z 1.94, p < 0.01) or who received a combination of
aspirin and clopidogrel for less than 9 months (OR Z 1.50,
p Z 0.031).Dual antiplatelet therapy duration as a predictor
The adjusted ORs for 1-year outcomes based on the dura-
tion of dual antiplatelet therapy with aspirin and clopi-
dogrel (<or 9 months) are presented in Table 4. The
probability of death across the spectrum of ACS wasstudy.
n (%)
6-mo FU 9-mo FU 1-y FU
) 579 (21.0) 927 (35.3) 1314 (51.7)
) 446 (16.2) 437 (16.6) 416 (16.4)
) 1584 (57.4) 1103 (42.0) 634 (24.9)
) 764 (27.7) 668 (25.4) 613 (24.1)
) 961 (34.8) 971 (37.0) 955 (37.5)
) 1630 (59.1) 1533 (58.4) 1500 (59.0)
) 507 (18.4) 508 (19.4) 515 (20.2)
) 1687 (61.1) 1587 (60.4) 1553 (61.1)
107 (3.9) 117 (4.5) 127 (5.0)
receptor blocker; FU Z follow-up.
Figure 2 Antiplatelet therapy during hospitalization and
follow-up.
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platelet therapy within 9 months of discharge (OR Z 7.64,
p < 0.01). The odds of death due to cardiovascular
complication were also higher in these patients (ORZ 3.5,
pZ 0.043). Overall, the probability of an adverse outcome
of death/MI/stroke was slightly higher in patients who
received a clopidogrel-aspirin combination for less than
9 months (OR Z 1.61, p Z 0.011). Fig. 4 shows the
KaplaneMeier survival curves according to the duration of
dual antiplatelet therapy. Dual antiplatelet therapy of
>9 months was significantly associated with lower mortality
(Fig. 4A) and lower adverse outcome of death/MI/stroke
(Fig. 4B).
Discussion
The main goal of the Taiwan ACS Full Spectrum Registry was
to identify the nation-wide practices in ACS management
from the point of index hospitalization to 1 year postTable 3 Reasons for clopidogrel discontinuation before
9 months of therapy (N Z 1162).
Reason Patients (%)
BNHI regulations 41.0
Doctor’s decision 25.4
Unknown 16.2
BMS implantation 5.0
Death 3.4
Cost 3.0
Adverse events 1.7
Change to other antiplatelet agent 1.3
Patient’s decision 1.3
Surgery 0.5
DES implantation 0.3
Warfarin use 0.3
Bleeding 0.3
Comorbidities 0.3
BMS Z bare-metal stent; BNHI Z Bureau of National Health
Insurance; DES Z drug-eluting stent.discharge. In this study, we present the association be-
tween various predictors and their outcomes at the end of
1 year after patient release from the hospital.
In our Taiwan ACS Full Spectrum Registry, the in-hospital
mortality rate was 1.8%, whereas the 1-year mortality rate
was 7.5% with the highest mortality being within the NSTEMI
subgroup (10.1%). This finding parallels results reported by
previous studies conducted in Australia (ACACIA)14 and
Canada (CACS).16 The mortality rates reported in ACACIA
and CACS were 7.5% and 7.2%, respectively. The proportion
of NSTEMI deaths in the ACACIA study was 10.5%, while the
highest proportion of death in the CACS registry was in the
non-Q-wave MI (NQMI), reported at 10.0%.
One of the major hindrances to successfully managing
ACS is the lack of adherence to guidelines pertaining to
secondary preventive therapies. Similar to the observations
made in the Australian14 and Canadian registry,16 we high-
light the underutilization of recommended postdischarge
treatment, especially dual antiplatelet therapy, in Taiwa-
nese ACS patients. The exact duration of clopidogrel ther-
apy required in ACS patients is somewhat unclear, given the
adverse events seen after clopidogrel cessation at any
time-point.20 Studies have shown the benefits of long-term
dual antiplatelet therapy in ACS patients21 and the
extended use of clopidogrel has been associated with a
reduced risk of death or MI.22 A report from the e-SELECT
registry has indicated that patients showed good compli-
ance with international guidelines for antiplatelet therapy
during the first year; the incidence of stent thrombosis and
major bleeding was low.23 The large global registry, GRACE,
has also demonstrated evidence of a change in practice for
pharmacological therapy, including increase in use of beta
blocker, statin, and thienopyridines in patients with ACS,
accompanied by significant decreases in the rates of in-
hospital death, recurrent or new MI.24 In Taiwan, the T-
ACCORD study has shown that dual antiplatelet therapy for
at least 9 months is associated with lower rates of 1-year
mortality.17 Moreover, recent updates on guidelines for
ACS management recommend dual antiplatelet therapy
with aspirin and clopidogrel for at least 1-year post
discharge.4 Despite this, the number of patients receiving
dual therapy in our study dramatically decreased from
74.8% at discharge to 24.9% at the 1-year follow-up visit. At
the same time, the number of patients receiving aspirin
only went up by 46.2%, indicating a shift in therapy from
the aspirin-clopidogrel combination to aspirin alone. The
major reason cited for clopidogrel discontinuation was the
BNHI regulations. However, this is contentious since BNHI
reimburses up to 9 months of dual antiplatelet therapy for
ACS patients, highlighting the need for periodically assess-
ing and updating physician awareness on insurance policies.
The other major reason for clopidogrel discontinuation was
as per physicians’ clinical judgment. The significance of this
deviation from guidelines is demonstrated in the increased
probability of all-cause death (Fig. 4A) and incidence of
death/MI/stroke (Fig. 4B) as well as increased odds of all-
cause death (OR Z 7.64, p < 0.01) and adverse outcome
of death/MI/stroke (ORZ 1.61, pZ 0.011) in patients who
received the aspirin-clopidogrel combination for
<9 months.
Besides antiplatelet agents, a number of other drugs
such as lipid-lowering statins, beta blockers, and agents
Figure 3 ORs for different predictors of 1-year clinical outcomesddeath/MI/stroke. *p < 0.01. ACEI Z angiotensin-converting
enzyme inhibitor; ARB Z angiotensin receptor blocker; CVD Z cardiovascular disease; DES Z drug-eluting stent; LVEF Z left
ventricular ejection fraction; NSTEMI Z non-ST-segment elevation myocardial infarction; OR Z odds ratio; PCI Z percutaneous
coronary intervention.
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shown to contribute to favorable outcomes in ACS pa-
tients.25,26,27,28 Despite this, quite a few large registries
show that the long-term use of these therapies is subopti-
mal,11,12,29,30 and the figures reported in our study reflect
this observation. Consequently, we observed a marked
correlation between 1-year survival and prescription of
such recommended therapies.
The use of dual antiplatelet therapy is a major predictor
of long-term adverse outcomes following ACS. Data from
the CURE study has shown favorable prognosis in ACS pa-
tients treated with dual antiplatelet therapy for a period of
9 months.31 In 2011, published data from Roberta et al
concluded that the premature discontinuation of anti-
platelet therapy is strongly associated with increased car-
diovascular events, including stent thrombosis and death.
Patients with early discontinuation of antiplatelet therapy
within 1 year experienced a greater incidence of major
adverse cardiac events (MACE), overall mortality, and car-
diovascular death compared to those who did not discon-
tinue the antiplatelet therapy early.32 In our study, patients
who received a combination of clopidogrel and aspirin for<9 months had higher odds (OR Z 1.50, p Z 0.031) of
adverse outcomes than those who had the combination for
a longer duration, while those who discontinued anti-
platelet therapy had almost twice the odds (OR Z 1.94,
p < 0.01) of experiencing death/MI/stroke.
Amongst the ACS subtypes, NSTEMI is most often asso-
ciated with unfavorable outcomes. This was no different in
our registry and NSTEMI patients had a higher mortality rate
and significantly higher odds of experiencing an adverse
outcome compared to the STEMI and UA cases.
Renal dysfunction is a major cardiovascular risk factor
and patients with chronic kidney disease have a high
probability of dying from ACS-related causes.33 Kidney
disease is an independent long-term predictor of ACS
outcome,34 especially in patients with NSTEMI. We
observed that the patients in our registry who had a history
of chronic renal failure had the highest odds (OR Z 4.54,
p < 0.01) of an unfavorable outcome at 1 year. This finding
serves to provide impetus to evaluating the role of renal
disease in ACS outcomes.
Until recently, in-hospital bleeding in ACS patients was
thought to have a positive association with short-term
Table 4 Adjusted OR for 1-year outcomes of aspirin-
clopidogrel combination of <9 months versus 9 months.
1-y outcome <9 mo (%) 9 mo (%) OR (95% CI) p
Death
Overall 4.69 0.64 7.64
(3.08e18.96)
<0.01
STEMI 3.36 0.45 7.65
(1.82e32.09)
<0.01
NSTEMI or
UA
6.54 0.88 7.86
(2.42e25.53)
<0.01
Cardiovascular death
Overall 1.33 0.38 3.50
(1.04e11.77)
0.043
STEMI 1.30 0.23 5.81
(0.75e44.85)
0.091
NSTEMI or
UA
1.37 0.59 2.35
(0.50e10.92)
0.277
MI
Overall 2.79 4.22 0.65
(0.41e1.03)
0.067
STEMI 3.15 3.62 0.86
(0.46e1.61)
0.646
NSTEMI or
UA
2.28 5.00 0.44
(0.22e0.90)
0.024
Stroke
Overall 1.14 0.38 2.99
(0.88e10.19)
0.079
STEMI 1.30 0.23 5.81
(0.75e44.85)
0.091
NSTEMI or
UA
0.91 0.59 1.56
(0.31e7.76)
0.589
Death/MI/Stroke
Overall 7.98 5.12 1.61
(1.11e2.32)
0.011
STEMI 7.16 4.07 1.82
(1.06e3.10)
0.029
NSTEMI or
UA
9.13 6.47 1.45
(0.87e2.41)
0.149
CI Z confidence interval; MI Z myocardial infarction;
NSTEMI Z non-ST-segment elevation myocardial infarction;
OR Z odds ratio; STEMI Z ST-segment elevation myocardial
infarction; UA Z unstable angina.
Figure 4 Kaplan-Meier survival analysis of patients on dual
antiplatelet therapy at <9 months or 9 months. (A) All-cause
death at 1 year. (B) Probability of death/MI/stroke at 1 year.
MI Z myocardial infarction.
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However, data in recent years from the ACUITY trial has
shown that on the contrary, major bleeding during hospi-
talization poses a 3.5-fold risk of death in ACS patients.36
New-onset atrial fibrillation (AF) has been shown to be
associated with short- and long-term mortality in ACS pa-
tients37 while the role of new-onset ventricular arrhythmia
(VA) in ACS prognosis is only recently coming to light. A
recent post hoc analysis of the GRACE registry showed that
in-hospital fatality rate was 52.0% in patients who devel-
oped VA during hospitalization. In addition, new-onset VA
was associated with higher 6-month mortality rate
(OR Z 1.57).38 It was interesting to note that in our study,
patients who had new-onset VA had higher odds
(OR Z 3.43, p < 0.01) than those who had new-onset AF
(OR Z 1.98, p Z 0.011).Other independent predictors of favorable outcome at
1-year post discharge were the use of drug eluting stents
during hospitalization (OR Z 0.55, p < 0.01) and prescrip-
tion of clopidogrel (OR Z 0.34, p < 0.01) and aspirin
(OR Z 0.35, p < 0.01) at discharge.
As mentioned in our previous study, the major limitation
of the ACS Full Spectrum Registry lies in its nonrandomized,
observational nature. Thus, the observed associations may
not necessarily be causal by nature. Moreover, although our
observations are in accord with those reported in other
studies, it is not possible to pinpoint the cause of non-
adherence to guidelines in the management of ACS in
Taiwan. However, these findings set the stage for identifi-
cation of problems in the implementation of policy and
local guidelines.
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